Nancy J. Hutson - Oct 15, 2021 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Director
Signature
/s/ Alane P. Barnes, by power of attorney
Stock symbol
BCRX
Transactions as of
Oct 15, 2021
Transactions value $
-$1,253,550
Form type
4
Date filed
10/19/2021, 04:21 PM
Previous filing
May 20, 2022
Next filing
Nov 2, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Options Exercise $87.3K +30K +46.1% $2.91 95.1K Oct 15, 2021 Direct F1
transaction BCRX Common Stock Options Exercise $154K +30K +31.55% $5.13 125K Oct 15, 2021 Direct F1
transaction BCRX Common Stock Options Exercise $25.7K +15K +11.99% $1.71 140K Oct 15, 2021 Direct F1
transaction BCRX Common Stock Options Exercise $96.6K +30K +21.42% $3.22 170K Oct 15, 2021 Direct F1
transaction BCRX Common Stock Sale -$1.62M -105K -61.74% $15.40 65.1K Oct 15, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Automatic Stock Option Grant Options Exercise $0 -30K -100% $0.00* 0 Oct 15, 2021 Common Stock 30K $2.91 Direct F1
transaction BCRX Automatic Stock Option Grant Options Exercise $0 -30K -100% $0.00* 0 Oct 15, 2021 Common Stock 30K $5.13 Direct F1
transaction BCRX Automatic Stock Option Grant Options Exercise $0 -15K -100% $0.00* 0 Oct 15, 2021 Common Stock 15K $1.71 Direct F1
transaction BCRX Automatic Stock Option Grant Options Exercise $0 -30K -100% $0.00* 0 Oct 15, 2021 Common Stock 30K $3.22 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.
F2 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.13 to $15.51. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.